Prothena Corporation plc
PRTAHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeProthena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. With a market capitalization of $453.4M, it sits in small-cap territory. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Market Cap
$453.4M
Beta
-0.31
P/E (TTM)
—
P/E (Fwd)
-6.61
EPS (TTM)
$-2.87
EPS (Fwd)
$-1.31
ROE
-40.3%
ROA
-13.8%
Cash
$329.5M
Total Debt
$7.7M
Free CF
-$31.6M
52W Change
38.3%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $329.5M in cash comfortably exceeding the $7.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$31.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -40.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $53.9M to $9.7M.
The relatively low beta of -0.31 suggests PRTA is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Prothena Corporation plc and its sector.